Fig. 3From: A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndromeDistribution of Clinical Global Impression-Improvement (CGI-I) Score at end of treatment. Comparison of CGI-I results between ganaxolone and placebo treatment arms in intention-to-treat population (n = 55). There was no statistically significant difference in CGI-I scores between treatment arms (p = 0.45)Back to article page